Top Suppliers:I want be here
  • DC Chemicals Limited
  • China
  • Product Name: CHIR-090
  • Price: $550.0/100mg $1000.0/250mg $1900.0/1g
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

728865-23-4

728865-23-4 structure
728865-23-4 structure
  • Name: CHIR-090
  • Chemical Name: N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[2-[4-(morpholin-4-ylmethyl)phenyl]ethynyl]benzamide
  • CAS Number: 728865-23-4
  • Molecular Formula: C24H27N3O5
  • Molecular Weight: 437.488
  • Catalog: Signaling Pathways Anti-infection Bacterial
  • Create Date: 2017-02-12 15:16:32
  • Modify Date: 2024-01-02 07:14:43
  • CHIR-090 is a potent, slow, tight-binding inhibitor of the LpxC deacetylase. It binds to E. coli LpxC with a Ki of 4.0 nM.

Name N-[(2S,3R)-3-hydroxy-1-(hydroxyamino)-1-oxobutan-2-yl]-4-[2-[4-(morpholin-4-ylmethyl)phenyl]ethynyl]benzamide
Synonyms CHIR-090
CHIR-090||CHIR090
N-[(2S,3R)-3-Hydroxy-1-(hydroxyamino)-1-oxo-2-butanyl]-4-{[4-(4-morpholinylmethyl)phenyl]ethynyl}benzamide
(2S,3R)-N-(2-hydroxy-1-hydroxycarbamoylpropyl)-4-(4-morpholin-4-ylmethylphenylethynyl)benzamide
N-{(1s,2r)-2-Hydroxy-1-[(Hydroxyamino)carbonyl]propyl}-4-{[4-(Morpholin-4-Ylmethyl)phenyl]ethynyl}benzamide
Benzamide, N-[(1S,2R)-2-hydroxy-1-[(hydroxyamino)carbonyl]propyl]-4-[2-[4-(4-morpholinylmethyl)phenyl]ethynyl]-
C90
Description CHIR-090 is a potent, slow, tight-binding inhibitor of the LpxC deacetylase. It binds to E. coli LpxC with a Ki of 4.0 nM.
Related Catalog
Target

Ki: 4 nM (Escherichia coli LpxC)[1]

In Vitro CHIR-090 is a potent, slow, tight-binding inhibitor of the LpxC deacetylase from the hyperthermophile Aquifex aeolicus, and it has excellent antibiotic activity against P. aeruginosa and E. coli, as judged by disk diffusion assays. CHIR-090 is also a two-step slow, tight-binding inhibitor of Escherichia coli LpxC with Ki=4 nM. CHIR-090 at low nM levels inhibits LpxC orthologues from diverse Gram-negative pathogens, including Pseudomonas aeruginosa, Neisseria meningitidis, and Helicobacter pylori. In contrast, CHIR-090 is a relatively weak competitive and conventional inhibitor (lacking slow, tight-binding kinetics) of LpxC from Rhizobium leguminosarum (Ki=340 nM), a Gram-negative plant endosymbiont that is resistant to this compound. An E. coli construct in which the chromosomal lpxC gene is replaced by R. leguminosarum lpxC is resistant to CHIR-090 up to 100 μg/mL, or 400 times above the minimal inhibitory concentration for wild-type E. coli. CHIR-090, a very potent, slow, tight-binding inhibitor of Aquifex aeolicus LpxC, the sequence of which is 31 % identical to E. coli LpxC. CHIR-090 has remarkable antibiotic activity against E. coli and P. aeruginosa, comparable to ciprofloxacin, as judged by disk diffusion assays[1].
In Vivo CHIR-090 is a potent antibiotic against E. coli and inhibits E. coli LpxC activity in vitro in the low nM range. E. coli W3110 colonies resistant to 1 μg/mL CHIR-090 are not observed without prior chemical mutagenesis. A strain of E. coli W3110 is able to grow on LB agar plates containing 1 to 10 μg/mL CHIR-090, which is 4 to 40 times above the MIC of 0.25 μg/mL under our conditions for wild-type E. coli W3110. The doubling time of W3110RL is 40 min in the presence of 1 μg/mL CHIR-090, which is exactly the same rate as wild-type in the absence of inhibitor. Wild-type cells stopped growing after about 2 h in the presence of 1 μg/mL CHIR-090[1].
Kinase Assay Disk diffusion is conducted, except that 10 μg of each antibiotic compound is used per filter. Growth in liquid medium in the presence of CHIR-090 is evaluated as follows: cells from overnight cultures are inoculated into 50 mL portions of LB broth at an A600 of 0.02 and grown with shaking at 30°C. When the A600 reaches 0.15, parallel cultures are treated with either 6 μL of 500 μg/mL CHIR-090 in DMSO or 6 μL of DMSO. To assess cumulative growth, cultures are maintained in log phase growth by 10-fold dilution into pre-warmed medium, containing the same concentrations of DMSO or DMSO/CHIR-090, whenever the A600 reaches 0.4. The minimal inhibitory concentration is defined as the lowest antibiotic concentration at which no measurable bacterial growth is observed in LB medium containing 1% DMSO (v/v), when inoculated at a starting density of A600=0.01. Cultures are incubated with shaking for 24 h at 30°C in the presence of CHIR-090. Experiments are performed in triplicate[1].
References

[1]. Barb AW, et al. Inhibition of lipid A biosynthesis as the primary mechanism of CHIR-090 antibiotic activity in Escherichia coli. Biochemistry. 2007 Mar 27;46(12):3793-802.

[2]. Barb AW, et al. Structure of the deacetylase LpxC bound to the antibiotic CHIR-090: Time-dependent inhibition and specificity in ligand binding. Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18433-8.

[3]. Tan JH, et al. In Vitro and In Vivo Efficacy of an LpxC Inhibitor, CHIR-090, Alone or Combined with Colistin against Pseudomonas aeruginosa Biofilm. Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02223-16.

Density 1.3±0.1 g/cm3
Molecular Formula C24H27N3O5
Molecular Weight 437.488
Exact Mass 437.195068
PSA 114.62000
LogP 1.23
Index of Refraction 1.650
Storage condition 2-8℃

~81%

728865-23-4 structure

728865-23-4

Literature: ACHAOGEN, INC. Patent: WO2008/154642 A2, 2008 ; Location in patent: Page/Page column 93 ; WO 2008/154642 A2

~%

728865-23-4 structure

728865-23-4

Literature: Hale, Michael R.; Hill, Pamela; Lahiri, Sushmita; Miller, Matthew D.; Ross, Philip; Alm, Richard; Gao, Ning; Kutschke, Amy; Johnstone, Michele; Prince, Bryan; Thresher, Jason; Yang, Wei Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 8 p. 2362 - 2367

~%

728865-23-4 structure

728865-23-4

Literature: Hale, Michael R.; Hill, Pamela; Lahiri, Sushmita; Miller, Matthew D.; Ross, Philip; Alm, Richard; Gao, Ning; Kutschke, Amy; Johnstone, Michele; Prince, Bryan; Thresher, Jason; Yang, Wei Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 8 p. 2362 - 2367

~%

728865-23-4 structure

728865-23-4

Literature: Hale, Michael R.; Hill, Pamela; Lahiri, Sushmita; Miller, Matthew D.; Ross, Philip; Alm, Richard; Gao, Ning; Kutschke, Amy; Johnstone, Michele; Prince, Bryan; Thresher, Jason; Yang, Wei Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 8 p. 2362 - 2367

~%

728865-23-4 structure

728865-23-4

Literature: Hale, Michael R.; Hill, Pamela; Lahiri, Sushmita; Miller, Matthew D.; Ross, Philip; Alm, Richard; Gao, Ning; Kutschke, Amy; Johnstone, Michele; Prince, Bryan; Thresher, Jason; Yang, Wei Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 8 p. 2362 - 2367

~%

728865-23-4 structure

728865-23-4

Literature: Hale, Michael R.; Hill, Pamela; Lahiri, Sushmita; Miller, Matthew D.; Ross, Philip; Alm, Richard; Gao, Ning; Kutschke, Amy; Johnstone, Michele; Prince, Bryan; Thresher, Jason; Yang, Wei Bioorganic and Medicinal Chemistry Letters, 2013 , vol. 23, # 8 p. 2362 - 2367